Researchers from Peking University, China, have identified a new potential therapeutic target for drugs to improve the effectiveness of diabetes treatment.
Researchers from the Peking University Health Science Center believe that microbial dipeptidyl peptidase 4 (DPP4) from the gut microbiota is an important therapeutic target for the management of type 2 diabetes.
DPP4 can degrade glucagon in the host and contribute to damage to glucose homeostasis, as shown in the joint study conducted by Peking University Health Science Center, Peking University Third Hospital and Peking University School of Chemistry and Molecular Engineering.
The researchers also found that the enrichment of peptidases in the host body would significantly reduce the clinical efficacy of Sitagliptin, a drug commonly used to treat diabetes, because Sitagliptin could not effectively inhibit DPP4 activity.
Efforts are underway to find ways to inhibit the activity of the DPP4 enzyme, which holds the potential to enhance the effectiveness of existing drugs and even discover new therapies.
According to the study, this discovery is expected to have important implications for further understanding the pathogenesis of diabetes and for enhancing the effectiveness of related drug therapies.
2023-08-07 19:17:00
#revolutionary #discovery #China #treatment #diabetes. #Details
